Renier J. Brentjens

8 ta ish

Cornell University

1. A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

   Prasad S. Adusumilli, Marjorie G. Zauderer, Isabelle Rivière +27

   MaqolaOAOchiq kirish20213 iqtibos

   ABIABI:AkademIndex/2026.other.102892

2. The Basic Principles of Chimeric Antigen Receptor Design

   Michel Sadelain, Renier J. Brentjens, Isabelle Rivière

   Sharh maqola20133 iqtibos

   ABIABI:AkademIndex/2026.other.340840

3. GPRC5D-Targeted CAR T Cells for Myeloma

   Sham Mailankody, Sean M. Devlin, Jonathan Landa +35

   MaqolaOAOchiq kirish20222 iqtibos

   ABIABI:AkademIndex/2026.other.082883

4. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning

   Hollie J. Pegram, James Lee, Erik Hayman +4

   MaqolaOAOchiq kirish20122 iqtibos

   ABIABI:AkademIndex/2026.other.102823

5. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors <i>in vivo</i>

   Mythili Koneru, Terence J. Purdon, David R. Spriggs +2

   MaqolaOAOchiq kirish20152 iqtibos

   ABIABI:AkademIndex/2026.other.102831

6. IL-18–secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models

   Janneke E. Jaspers, Jonathan F. Khan, William D. Godfrey +4

   MaqolaOAOchiq kirish20232 iqtibos

   ABIABI:AkademIndex/2026.other.102936

7. Overcoming Antigen Escape with CAR T-cell Therapy

   Hollie J. Jackson, Renier J. Brentjens

   Boshqa20152 iqtibos

   ABIABI:AkademIndex/2026.other.340845

8. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

   Melody Smith, Anqi Dai, Guido Ghilardi +46

   Maqola20222 iqtibos

   ABIABI:AkademIndex/2026.other.480531